Ceftobiprole (active moiety of ceftobiprole medocaril)

Synonym(s): Zevtera

Class: Beta-lactam (cephalosporin)

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Basilea's broad-spectrum antibiotic ceftobiprole gained regulatory approval in thirteen European countries for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) in adults, excluding ventilator-associated pneumonia (VAP). The drug was launched in Germany in the fourth quarter of 2014 with further European launches planned for 2015. Not approved by the FDA, so no US launch as of yet.
Institute where first reported:	Basilea Pharmaceutica, Switzerland
Year first mentioned:	2002
Highest developmental phase:	Approved by FDA in 2024
Development status:	Approved

Chemical structure(s):
Canonical SMILES:	C1CNC[C@@H]1N2CC/C(=C\C3=C(C(=O)O)N4C(=O)[C@H]([C@H]4SC3)NC(=O)/C(=N\O)/C5=NSC(=N5)N)/C2=O
Isomeric SMILES:	C1CNC[C@@H]1N2CC/C(=C\C3=C(N4[C@@H]([C@@H](C4=O)NC(=O)/C(=N\O)/C5=NSC(=N5)N)SC3)C(=O)O)/C2=O
InChI:	InChI=1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10,12,18,22,34H,1-4,6-7H2,(H,23,29)(H,32,33)(H2,21,24,26)/b8-5+,25-11-/t10-,12-,18-/m1/s1
InChI Key:	VOAZJEPQLGBXGO-SDAWRPRTSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/135413542

External links:
Guide to Pharmacology:	ceftobiprole
Main Source:	https://www.basilea.com/news/news/basilea-announces-positive-results-of-phase-3-target-study-with-antibiotic-ceftobiprole-in-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-absssi?type=1546938654
Citations:	https://www.basilea.com/fileadmin/user_upload/pressreleases/1803157-en-01-201904112_Basilea_Press_release_ECCMID_EN.pdf?v=1565587522 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC126986/ https://www.tandfonline.com/doi/pdf/10.1080/14787210.2019.1667229
Patent:	CN103275104B